Group 1 - ANI Pharmaceuticals, Inc. will present at two upcoming investor conferences: the Guggenheim Inaugural Healthcare Innovation Conference on November 13, 2024, and the Jefferies London Healthcare Conference on November 20, 2024 [1] - The presentations will be made by Nikhil Lalwani, President and CEO, and Stephen Carey, CFO [1] - Live and archived webcasts of the presentations will be available on the company's website for 90 days [1] Group 2 - ANI Pharmaceuticals is a diversified biopharmaceutical company focused on developing, manufacturing, and commercializing innovative therapeutics [2] - The company aims for sustainable growth through its Rare Disease business, Generics business, and Established Brands business [2] - ANI Pharmaceuticals markets products in various therapeutic areas including ophthalmology, rheumatology, nephrology, neurology, and pulmonology [2]

Wall Street expects a year-over-year decline in earnings on higher revenues when ANI Pharmaceuticals (ANIP) reports results for the quarter ended September 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on November 8, 2024, might help the stock move higher if these key numbers are bett ...

PRINCETON, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ: ANIP) today announced that the Company will release its third quarter 2024 financial results on Friday, November 8, 2024, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease, will host a conference call to discuss the results as follows: Date Friday, Novem ...

Company Overview - ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company focused on developing, manufacturing, and marketing high-quality branded and generic prescription pharmaceutical products, particularly for diseases with high unmet medical needs [2] - The company aims to achieve sustainable growth by scaling its Rare Disease business, enhancing its Generics business through improved research and development, and leveraging its U.S.-based manufacturing capabilities [2] Recent Developments - ANI Pharmaceuticals announced the launch of Estradiol Gel, 0.06%, following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) [1] - Estradiol Gel, 0.06% is the generic version of the reference listed drug EstroGel® Gel, 0.06% [1] - The U.S. annual sales for Estradiol Gel, 0.06% are approximately $16.7 million based on August 2024 moving annual total (MAT) IQVIA data [1]

PRINCETON, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company will present new pre-clinical data highlighting its membranous nephropathy (MN) research during two poster presentations at the American Society of Nephrology (ASN) Kidney Week 2024 in San Diego, CA, October 23-27. "We are excited to share our data with the ASN 2024 community. These data shed light of the potential role of melanocortin receptors in the underlying ...

Core Viewpoint - ANI Pharmaceuticals is well-positioned to continue its earnings-beat streak in upcoming reports, having surpassed earnings estimates consistently in recent quarters [1][2]. Earnings Performance - ANI Pharmaceuticals has topped earnings estimates by an average of 16.57% over the last two quarters [1]. - In the last reported quarter, ANI achieved earnings of $1.02 per share, exceeding the Zacks Consensus Estimate of $0.93 per share by 9.68% [1]. - For the previous quarter, ANI's actual earnings were $1.21 per share against an expected $0.98 per share, resulting in a surprise of 23.47% [1]. Earnings Estimates and Predictions - Estimates for ANI have been trending higher due to its history of earnings surprises [2]. - The stock has a positive Zacks Earnings ESP of +2.50%, indicating bullish sentiment among analysts regarding its near-term earnings potential [3]. - The combination of a positive Earnings ESP and a Zacks Rank 1 (Strong Buy) suggests a high likelihood of another earnings beat [3]. Importance of Earnings ESP - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, reflecting the latest analyst revisions [3]. - A positive Earnings ESP enhances the predictive power of potential earnings beats, while a negative value does not necessarily indicate an earnings miss [3][4]. - Utilizing the Earnings ESP Filter can help identify stocks with the best potential for success before earnings reports [4].

Piper Sandler has initiated coverage on ANI Pharmaceuticals ANIP, an integrated specialty pharmaceutical firm that develops and markets branded and generic medicines.The analyst notes that ANI’s business model has significantly transformed, shifting from a primary emphasis on generics to a new focus on integrating high-margin brand assets aimed at rare diseases. Cortrophin Gel (adrenocorticotropic hormone (ACTH)), the company’s lead asset, has been the centerpiece of that evolution.Cortrophin gel sales more ...

Biotech Forum Discussion - The Biotech Forum has been focused on lucrative buy-write or covered call opportunities on selected biotech stocks over the past several months [1] - The forum offers real-time trading ideas and insights from seasoned biotech investors [1] ANI Pharmaceuticals Spotlight - ANI Pharmaceuticals Inc (NASDAQ: ANIP) is highlighted as a small but growing biopharma company [1] - The equity is considered one of the few reasonable growth at a reasonable price (GARP) stocks in the biotech sector [1] The Biotech Forum Services - The Biotech Forum provides a model portfolio featuring 12-20 high upside biotech stocks [1] - The forum offers live chat for discussing trade ideas, weekly research, and option trades [1] - Market commentary and portfolio updates are provided every weekend [1]

ANI Pharmaceuticals (ANIP) closed the last trading session at $56.79, gaining 2.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $81.20 indicates a 43% upside potential.The mean estimate comprises five short-term price targets with a standard deviation of $13.70. While the lowest estimate of $60 indicates a 5.7% increase from the current price level, the most optimistic analyst e ...

Core Insights - The Zacks Rank system emphasizes earnings estimates and revisions to identify winning stocks, with a focus on value investing as a popular strategy in various market conditions [1] - Zacks has introduced the Style Scores system to highlight stocks with specific characteristics, particularly those with high grades in the "Value" category, which are considered strong value stocks when combined with a high Zacks Rank [1] Company Summary: ANI Pharmaceuticals (ANIP) - ANI Pharmaceuticals currently holds a Zacks Rank of 2 (Buy) and has received a Value grade of A, indicating strong potential for value investors [2] - The company's price-to-book (P/B) ratio is 2.64, which is favorable compared to the industry average of 3.88. Over the past 12 months, ANIP's P/B ratio has fluctuated between 2.31 and 3.30, with a median of 2.83 [2] - ANI Pharmaceuticals has a price-to-cash flow (P/CF) ratio of 12.75, which is attractive relative to the industry average of 15.70. The P/CF ratio has ranged from 11.93 to 19.50 over the past 52 weeks, with a median of 13.70 [2] - These metrics suggest that ANI Pharmaceuticals is likely undervalued at present, especially when considering its strong earnings outlook, making it an impressive value stock [3]